The Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma) drugs in development market research report provides comprehensive information on the therapeutics under development for Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma) and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma) by five companies/universities/institutes. The top development phase for Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma) is preclinical with four drugs in that stage. The Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma) pipeline has six drugs in development by companies and one by universities/ institutes. Some of the companies in the Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma) pipeline products market are: Graviton Bioscience, Cervello Therapeutics and Neurelis.
The key targets in the Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma) pipeline products market include Rho Associated Protein Kinase 2, Rho Associated Protein Kinase 1, and Free Radical.
The key mechanisms of action in the Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma) pipeline product include Rho Associated Protein Kinase 2 Inhibitor with five drugs in Phase I. The Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma) pipeline products include two routes of administration with the top ROA being Oral and two key molecule types in the Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma) pipeline products market including Small Molecule, and Recombinant Protein.
Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma) overview
Cavernous hemangioma is also known as cerebral cavernous malformation (CCM), cavernoma, or cavernous angioma. It is an abnormal tangle of tightly packed, thin-walled capillaries that are prone to bleeding. Symptoms include seizures, blurred vision, double vision, loss of vision, weakness in arms or legs, facial drooping, unsteady walk, and headaches. Diagnostic tests include susceptibility weighted imaging (SWI) to look for small areas of bleeding, orbital echography, and tonometry. Treatments include craniotomy and stereotactically assisted craniotomy.
For a complete picture of Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
